Audentes Therapeutics Inc (NASDAQ:BOLD) – Investment analysts at Wedbush cut their FY2022 earnings estimates for Audentes Therapeutics in a research report issued on Friday. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of $12.00 for the year, down from their previous forecast of $12.83. Wedbush currently has a “Outperform” rating and a $56.00 target price on the stock.
Several other research firms have also weighed in on BOLD. BidaskClub lowered Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. Zacks Investment Research lowered Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. Leerink Swann reissued an “outperform” rating and issued a $29.00 target price (up previously from $22.00) on shares of Audentes Therapeutics in a research note on Wednesday, November 15th. HC Wainwright set a $37.00 target price on Audentes Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 4th. Finally, Mizuho started coverage on Audentes Therapeutics in a research note on Monday, February 12th. They issued a “neutral” rating and a $26.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $35.56.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.09.
In other Audentes Therapeutics news, major shareholder Orbimed Advisors Llc sold 421,638 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $35.17, for a total value of $14,829,008.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 18,000 shares of the stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The disclosure for this sale can be found here. Insiders sold 1,087,707 shares of company stock worth $38,055,301 in the last three months. Insiders own 47.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in the business. Teachers Advisors LLC increased its holdings in shares of Audentes Therapeutics by 12.7% in the fourth quarter. Teachers Advisors LLC now owns 30,347 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 3,421 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Audentes Therapeutics in the third quarter worth about $143,000. Nationwide Fund Advisors increased its holdings in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 6,384 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Audentes Therapeutics by 86.1% in the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 6,667 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Audentes Therapeutics in the fourth quarter worth about $208,000. Institutional investors own 67.35% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “FY2022 EPS Estimates for Audentes Therapeutics Inc (BOLD) Lowered by Wedbush” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/03/14/fy2022-eps-estimates-for-audentes-therapeutics-inc-bold-lowered-by-wedbush.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.